Urinary incontinence linked to increased risk of falling in older adults
December 17th 2021“Falls are the leading cause of accidental death in seniors, and many people don’t know that having bladder control problems makes you about twice as likely to fall over,” said William Gibson, MBChB, MRCP, PhD.
Trial of novel PSMA-PET imaging agent in prostate cancer hits enrollment milestone
December 9th 2021The PROPELLER trial is exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy.
Study identifies optimal extent of PLND by risk status with radical prostatectomy
December 2nd 2021"We sought to conduct a National Cancer Database analysis evaluating the impact of the extent of lymphadenectomy on survival outcomes for patients presenting with intermediate- and high-risk prostate cancer,” said Furkan Dursun, MD.
Expert compares PSMA imaging agents, discusses PSMA vs Axumin in prostate cancer
November 12th 2021Now that there are 2 FDA-approved PSMA-PET imaging agents, urologists and other clinicians are asking about the differences between them, as well as how PSMA-PET imaging compares to the previously approved next-generation imaging agent fluciclovine F 18.
Adding PSMA PET/CT imaging to mpMRI improves detection of significant prostate cancer
October 28th 2021"Combining mpMRI and 68Ga-PSMA PET/CT in a primary diagnostic setting could better identify where to target on biopsy, increasing the diagnostic yield, improving concordance with underlying tumor grade and therefore improving management recommendations," the authors wrote.
IL-15 superagonist N-803 shows strong clinical activity in papillary NMIBC
October 20th 2021Data from the phase 2/3 QUILT-3.032 trial showed that adding N-803 to BCG met the primary end point of disease-free survival in patients with BCG-unresponsive, high-grade non–muscle-invasive bladder cancer and papillary disease.
Optilume drug-coated balloon superior to standard care for recurrent anterior urethral strictures
October 14th 2021“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.